Evidence map›Paper›PMID 23015735›Full record

ArticlemBio2012

Cryptococcal genotype influences immunologic response and human clinical outcome after meningitis.

Darin L Wiesner, Oleksandr Moskalenko, Jennifer M Corcoran, Tami McDonald, Melissa A Rolfes, David B Meya, Henry Kajumbula, Andrew Kambugu, Paul R Bohjanen, Joseph F Knight and 2 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Molecular types, clinical profile, and exploratory virulence-associated phenotypes of clinical Cryptococcus isolates from Amazonas, Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  6. Article
  7. Journal of medical microbiology · 2026
    Article
  8. Review
  9. Cryptococcal Meningitis Treatment Beyond HIV: Recognizing the Need for Individualized Immune-Based Strategies.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. The hypervirulent Type-1/Type-17 phenotype ofInfection and immunity · 2025
    Article
  14. Article
  15. Article
  16. Antifungal Resistance in Cryptococcal Infections.Pathogens (Basel, Switzerland) · 2024
    Review
  17. Article
  18. Article
  19. Genotyping Analysis ofJournal of fungi (Basel, Switzerland) · 2023
    Article
  20. Importance of Clinical Isolates inJournal of fungi (Basel, Switzerland) · 2023
    Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Darin L WiesnerDepartment of Microbiology, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.
Oleksandr Moskalenko
Jennifer M Corcoran
Tami McDonald
Melissa A Rolfes
David B Meya
Henry Kajumbula
Andrew Kambugu
Paul R Bohjanen
Joseph F Knight
David R Boulware
Kirsten Nielsen
University of Minnesota Medical Center · USMakerere University · UGMinnesota Department of Natural Resources · USUniversity of Minnesota · US

Funding

Trial for the Optimal Timing of HIV Therapy after Cryptococcal MeningitisU01AI089244 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R · 2010 to 2014
$7.6M
Outcomes of Cryptococcal Meningitis in UgandaK24AI096925 · NIAID · UNIVERSITY OF MINNESOTA · PI BOHJANEN, PAUL R · 2011 to 2015
$1.0M
Immune Reconstitution Syndrome in HIV infected Persons in Resource-Limited AreasK23AI073192 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R · 2009 to 2012
$530k
A link between mating pheromone sensing and virulence of Cryptococcus neoformansK22AI070152 · NIAID · UNIVERSITY OF MINNESOTA · PI NIELSEN, KIRSTEN · 2008 to 2009
$267k
HIV Immune Reconstitution Inflammatory Syndrome in UgandaR03AI078750 · NIAID · UNIVERSITY OF MINNESOTA · PI BOHJANEN, PAUL R · 2008 to 2009
$151k
NIAID NIH HHS AI070152NIAID NIH HHS AI073192NIAID NIH HHS AI078750NIAID NIH HHS AI089244NIAID NIH HHS AI096925NIAID NIH HHS K22 AI070152NIAID NIH HHS K23 AI073192NIAID NIH HHS K24 AI096925NIAID NIH HHS R03 AI078750NIAID NIH HHS U01 AI089244
6 · The paper itself

Abstract

unlabelledIn sub-Saharan Africa, cryptococcal meningitis (CM) continues to be a predominant cause of AIDS-related mortality. Understanding virulence and improving clinical treatments remain important. To characterize the role of the fungal strain genotype in clinical disease, we analyzed 140 Cryptococcus isolates from 111 Ugandans with AIDS and CM. Isolates consisted of 107 nonredundant Cryptococcus neoformans var. grubii strains and 8 C. neoformans var. grubii/neoformans hybrid strains. Multilocus sequence typing (MLST) was used to characterize genotypes, yielding 15 sequence types and 4 clonal clusters. The largest clonal cluster consisted of 74 isolates. The results of Burst and phylogenetic analysis suggested that the C. neoformans var. grubii strains could be separated into three nonredundant evolutionary groups (Burst group 1 to group 3). Patient mortality was differentially associated with the different evolutionary groups (P = 0.04), with the highest mortality observed among Burst group 1, Burst group 2, and hybrid strains. Compared to Burst group 3 strains, Burst group 1 strains were associated with higher mortality (P = 0.02), exhibited increased capsule shedding (P = 0.02), and elicited a more pronounced Th(2) response during ex vivo cytokine release assays with strain-specific capsule stimulation (P = 0.02). The results of these analyses suggest that cryptococcal strain variation can be an important determinant of human immune responses and mortality. IMPORTANCE: Cryptococcus neoformans is a common life-threatening human fungal pathogen that is responsible for an estimated 1 million cases of meningitis in HIV-infected patients annually. Virulence factors that are important in human disease have been identified, yet the impacts of the fungal strain genotype on virulence and outcomes of human infection remain poorly understood. Using an analysis of strain variation based on in vitro assays and clinical data from Ugandans living with AIDS and cryptococcal infection, we report that strain genotype predicts the type of immune response and mortality risk. These studies suggest that knowledge of the strain genotype during human infections could be used to predict disease outcomes and lead to improved treatment approaches aimed at targeting the specific combination of pathogen virulence and host response.

Indexed as

Multilocus Sequence TypingAcquired Immunodeficiency SyndromeAdultCluster AnalysisCryptococcus neoformansDNA, FungalFemaleGenotypeHumansMaleMeningitis, CryptococcalMiddle AgedMycological Typing TechniquesPhylogenyProspective StudiesSurvival AnalysisDNA, Fungal

Identifiers

PMID23015735
PMCPMC3448160
OpenAlexW2046696762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.